NASDAQ: DXCM · Industrial Applications and Services · 10 alerts · CIK 1093557
Share price
$81.61Close, Nov 16
Market cap
$30.4B
Shares outstanding
372.95MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Dexcom Inc filings on SEC EDGAR ↗
Dexcom delivered 11% revenue growth and record new patient starts, raising full-year guidance while navigating a minor PBM contract loss and preparing for a landmark CMS coverage expansion for non-insulin type 2 patients.
DexCom reported revenue of $1.34 billion for the third quarter of 2026, representing growth over the $1.21 billion reported in the prior year period. Net income for the nine months ended September 30, 2026, increased to $723.7 million compared to $569.0 million in 2025, driven by higher gross profits and operating income.
Dexcom reported Q3 2026 revenue of $1.34 billion, representing 11% year-over-year growth, and raised its full-year 2026 revenue guidance to $5.20-$5.25 billion. Alongside the results, the company announced that its Board of Directors authorized a new $1.0 billion share repurchase program effective through December 31, 2027.
“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives. This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”
Dexcom EVP Chief People & Culture Off Sadie Stern Sells $202K of Stock
Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $78.62 a share, worth $202K in total on Oct 27, 2026. Shares held after the trade: 120,913 (-2.1%).
Dexcom EVP Chief Legal Compliance Off Michael Jon Brown Sells $145K of Stock
Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of Dexcom Inc at $85.48 a share, worth $145K in total on Oct 15, 2026. Shares held after the trade: 98,185 (-1.7%).
Dexcom EVP Chief People & Culture Off Sadie Stern Sells $221K of Stock
Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $86.15 a share, worth $221K in total on Sep 28, 2026. Shares held after the trade: 123,478 (-2.0%).
Dexcom Insider Nicholas Augustinos Sells $680K of Stock
Nicholas Augustinos sold 8,089 shares of Dexcom Inc at $84.02 to $84.04 a share (average $84.04) in 2 transactions, worth $680K in total between Sep 14, 2026 and Sep 15, 2026. Shares held after the trade: 29,293 (-18.2%).
Dexcom EVP Chief Legal Compliance Off Michael Jon Brown Sells $143K of Stock
Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of Dexcom Inc at $84.04 a share, worth $143K in total on Sep 15, 2026. Shares held after the trade: 99,885 (-1.7%).
Dexcom promoted Jereme Sylvain to the expanded role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with the promotion, Mr. Sylvain's annual base salary was increased to $767,000 with a target bonus opportunity of 75% of his base salary.
Dexcom EVP, Chief Financal Officer Jereme M. Sylvain Sells $303K of Stock
Jereme M. Sylvain, EVP, Chief Financal Officer, sold 3,638 shares of Dexcom Inc at $83.27 a share, worth $303K in total on Sep 10, 2026. Shares held after the trade: 146,828 (-2.4%).